LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

WuXi STA opens a new large scale continuous manufacturing plant at Changzhou site

WuXi STA opens a new large scale continuous manufacturing plant

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Merck and Orion collaborate for the development and commercialization of ODM-208

Orion to receive an upfront payment of USD 290 million

Heathcare startup MedTel to raise around USD 10mn in Series A

MedTel aims to raise series A for rapid business expansion, product improvement & conducting relevant clinical validation studies.

50% of heart attacks now happens in Indians below 50 years: says Expert

Younger Indians have a 10 times higher rate of heart attack

NADMED brings first CE-marked NAD+ analysis kit to the market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites

Lynparza gets positive opinion from EU CHMP as adjuvant treatment for germline BRCA-mutated early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival in patients

Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients

AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza

LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)